Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab

This article was originally published in RPM Report

Executive Summary

When it comes to Amgen, all eyes are on denosumab. That's as it should be: Amgen's future rides on the potential blockbuster. But investors shouldn't lose sight of Amgen's past and present: how the company manages the continued threats to Aranesp have important lessons for the biopharma sector as a whole-and for denosumab too.

You may also be interested in...

A Bad Day for Lucentis

On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.

The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS

The long-awaited Risk Evaluation & Mitigation Strategy for Aranesp and Procrit is here. For the oncology indication, it requires provider training program enrollment. It may not seem like the best outcome for Amgen and J&J, but there are some upsides.

The Slow Death of a Blockbuster

Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts